| Product Name | SSX |
|---|---|
| Antibody Type | Primary Antibodies |
| Antigen Alias | SSX1 antibody; Protein SSX1 antibody; Cancer/testis antigen 5.1 antibody; CT5.1 antibody; Synovial sarcoma, X breakpoint 1 antibody; SSX2 antibody; SSX2A antibody; SSX2B antibody; Protein SSX2 antibody; Cancer/testis antigen 5.2 antibody; CT5.2 antibody; Synovial sarcoma, X breakpoint 2 antibody; Tumor antigen HOM-MEL-40 antibody; SSX3 antibody; Protein SSX3 antibody;Cancer/testis antigen 5.3 antibody; CT5.3 antibody; SSX4 antibody; SSX4A antibody; SSX4B antibody; Protein SSX4 antibody; Cancer/testis antigen 5.4 antibody; CT5.4 antibody; SSX5 antibody; Protein SSX5 antibody; SSX6 antibody; Putative protein SSX6 antibody; SSX7 antibody; Protein SSX7 antibody; SSX8 antibody; Protein SSX8 antibody; SSX9 antibody; Protein SSX9 antibody; |
| Product description | The product of this gene belongs to the family of highly homologous synovial sarcoma X (SSX) breakpoint proteins. These proteins may function as transcriptional repressors. They are also capable of eliciting spontaneous humoral and cellular immune responses in cancer patients, and are potentially useful targets in cancer vaccine-based immunotherapy. This gene, and also the SSX2 and SSX4 family members, have been involved in t(X;18)(p11. 2;q11. 2) translocations that are characteristically found in all synovial sarcomas. This translocation results in the fusion of the synovial sarcoma translocation gene on chromosome 18 to one of the SSX genes on chromosome X. The encoded hybrid proteins are likely responsible for transforming activity. Alternative splicing of this gene results in multiple transcript variants. A related pseudogene has been identified on chromosome X. |
| Immunogen | The antiserum was produced against synthesized peptide derived from the C-terminal region of human SSX1/2/3/4/5/6/7/8/9. AA range:139-188 |
| Clonality | Polyclonal |
|---|---|
| Isotype | IgG |
| Host Species | Rabbit |
| Tested Applications | WBIHC |
| WB:1:500-1:2000 IHC:1:100-300 |
|
| Species Reactivity | Human |
| Concentration | 1mg/ml |
| Alternative Names | SSX1 antibody Protein SSX1 antibody Cancer/testis antigen 5.1 antibody CT5.1 antibody Synovial sarcoma X breakpoint 1 antibody SSX2 antibody SSX2A antibody SSX2B antibody Protein SSX2 antibody Cancer/testis antigen 5.2 antibody CT5.2 antibody Synovial sarcoma X breakpoint 2 antibody Tumor antigen HOM-MEL-40 antibody SSX3 antibody Protein SSX3 antibody Cancer/testis antigen 5.3 antibody CT5.3 antibody SSX4 antibody SSX4A antibody SSX4B antibody Protein SSX4 antibody Cancer/testis antigen 5.4 antibody CT5.4 antibody SSX5 antibody Protein SSX5 antibody SSX6 antibody Putative protein SSX6 antibody SSX7 antibody Protein SSX7 antibody SSX8 antibody Protein SSX8 antibody SSX9 antibody Protein SSX9 antibody |
|---|---|
| Molecular Weight(MW) | 25 kDa |
| SwissProt ID | Q16384 |
|---|
| Positive Control | Fibrosarcoma,Placenta,Skin,Synovial sarcoma, |
|---|---|
| Application Notes | WB:1:500-1:2000 IHC:1:100-300 |
| Form | Liquid |
|---|---|
| Storage Instructions | Store at +4℃ after thawing. Aliquot store at -20℃ or -80℃. Avoid repeated freeze / thaw cycles. |
| Storage Buffer | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
